[HTML][HTML] Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
S Verstovsek, AM Vannucchi, M Griesshammer… - …, 2016 - ncbi.nlm.nih.gov
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2
inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant …
inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant …
Somatic mutations in Philadelphia chromosome-negative myeloproliferative neoplasms
SF Cristina, B Polo, JF Lacerda - Seminars in hematology, 2018 - Elsevier
Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal …
thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal …
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the …
BACKGROUND This analysis of the myeloproliferative neoplasm (MPN) Landmark survey
evaluated gaps between patient perceptions of their disease management and physician …
evaluated gaps between patient perceptions of their disease management and physician …
Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology
YC Chia, MJ Siti Asmaa, M Ramli, PY Woon, MF Johan… - Diagnostics, 2023 - mdpi.com
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) include polycythaemia
vera, essential thrombocythaemia, and primary myelofibrosis. Unlike monogenic disorders …
vera, essential thrombocythaemia, and primary myelofibrosis. Unlike monogenic disorders …
Real-world treatments and thrombotic events in polycythemia vera patients in the USA
S Verstovsek, N Pemmaraju, NL Reaven, SE Funk… - Annals of …, 2023 - Springer
Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of
thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive …
thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive …
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b
A Qin, D Wu, J Liao, S Xie, H Chen, Y Gao… - Frontiers in …, 2024 - frontiersin.org
Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia
vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV …
vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV …
Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
R Mesa, S Verstovsek, JJ Kiladjian… - European journal of …, 2016 - Wiley Online Library
Objectives Polycythemia vera (PV)‐related symptoms may not be adequately controlled with
conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of …
conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of …
Health-related quality of life in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
N Brochmann, EM Flachs, AI Christensen, M Bak… - Cancers, 2020 - mdpi.com
Simple Summary The aim of this research was to investigate the health-related quality of life
(HRQoL) in patients with Philadelphia-negative myeloproliferative neoplasms (chronic blood …
(HRQoL) in patients with Philadelphia-negative myeloproliferative neoplasms (chronic blood …
Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review
S Parasuraman, M DiBonaventura, K Reith… - … Hematology & Oncology, 2015 - Springer
Background Hydroxyurea (HU) is among the most commonly used cytoreductive treatments
for polycythemia vera (PV), but previous research and clinical experience suggest that not …
for polycythemia vera (PV), but previous research and clinical experience suggest that not …
[PDF][PDF] Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms
N Soyer, İC Haznedaroğlu, M Cömert… - Turkish Journal of …, 2017 - jag.journalagent.com
Objective: Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera
(PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia …
(PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia …